Xeris Biopharma Holdings, Inc. (0A8E.L)

USD 3.29

(-4.76%)

Operating Income Summary of Xeris Biopharma Holdings, Inc.

Xeris Biopharma Holdings, Inc.'s latest annual operating income in 2024 was -44.01 Million USD , up 46.29% from previous year.
Xeris Biopharma Holdings, Inc.'s latest quarterly operating income in 2024 FY was -44.01 Million USD , up 46.29% from previous quarter.
Xeris Biopharma Holdings, Inc. reported an annual operating income of -81.94 Million USD in 2023, down 0.0% from previous year.
Xeris Biopharma Holdings, Inc. reported an annual operating income of -81.94 Million USD in 2022, up 28.84% from previous year.
Xeris Biopharma Holdings, Inc. reported a quarterly operating income of -44.01 Million USD for 2024 FY, up 46.29% from previous quarter.
Xeris Biopharma Holdings, Inc. reported a quarterly operating income of -14.24 Million USD for 2024 Q3, down -44.75% from previous quarter.

Annual Operating Income Chart of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Historical Annual Operating Income of Xeris Biopharma Holdings, Inc. (2024 - 2017)

Year	Operating Income	Operating Income Growth
2024	-44.01 Million USD	46.29%
2023	-81.94 Million USD	0.0%
2022	-81.94 Million USD	28.84%
2021	-115.15 Million USD	-37.84%
2020	-83.54 Million USD	-40.78%
2019	-59.34 Million USD	-122.85%
2018	-26.62 Million USD	-101.26%
2017	-13.23 Million USD	0.0%

Year	Operating Income	Operating Income Growth
2024 Q1	-4.91 Million USD	69.25%
2024 FY	-44.01 Million USD	46.29%
2024 Q3	-14.24 Million USD	-44.75%
2024 Q4	-8.18 Million USD	42.53%
2024 Q2	-9.84 Million USD	-100.31%
2023 FY	-81.94 Million USD	0.0%
2023 Q4	-15.97 Million USD	-20.35%
2023 Q3	-13.27 Million USD	16.91%
2023 Q2	-15.97 Million USD	14.91%
2023 Q1	-18.78 Million USD	0.72%
2022 Q2	-48.27 Million USD	-98.17%
2022 Q1	-24.35 Million USD	5.54%
2022 FY	-81.94 Million USD	28.84%
2022 Q4	-18.91 Million USD	34.94%
2022 Q3	-29.07 Million USD	39.77%
2021 Q3	-16.74 Million USD	13.46%
2021 Q2	-19.34 Million USD	-40.74%
2021 FY	-115.15 Million USD	-37.84%
2021 Q1	-13.74 Million USD	38.1%
2021 Q4	-25.78 Million USD	-54.04%
2020 FY	-83.54 Million USD	-40.78%
2020 Q1	-30.08 Million USD	11.68%
2020 Q4	-22.2 Million USD	21.41%
2020 Q3	-28.25 Million USD	13.86%
2020 Q2	-32.8 Million USD	-9.04%
2019 Q2	-20.31 Million USD	-35.94%
2019 Q4	-34.06 Million USD	-33.9%
2019 FY	-59.34 Million USD	-122.85%
2019 Q1	-14.94 Million USD	-20.93%
2019 Q3	-25.43 Million USD	-25.22%
2018 Q2	-9.2 Million USD	-21.62%
2018 FY	-26.62 Million USD	-101.26%
2018 Q4	-12.35 Million USD	-5.35%
2018 Q3	-11.73 Million USD	-27.38%
2018 Q1	-7.57 Million USD	-45.64%
2017 Q3	-4.64 Million USD	0.0%
2017 Q4	-5.19 Million USD	-11.83%
2017 FY	-13.23 Million USD	0.0%

Peer Operating Income Comparison of Xeris Biopharma Holdings, Inc.

Name	Operating Income	Operating Income Difference
Arrowhead Pharmaceuticals, Inc.	-205 Million USD	78.532%
Codexis, Inc.	-68.06 Million USD	35.345%
Viridian Therapeutics, Inc.	-254.45 Million USD	82.704%
Organovo Holdings, Inc.	-15.08 Million USD	-191.727%